Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) have earned an average recommendation of “Moderate Buy” from the nine analysts that are presently covering the stock, MarketBeat reports. Two analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $45.4286.

Several research analysts recently weighed in on KNSA shares. Wedbush upped their price target on Kiniksa Pharmaceuticals International from $38.00 to $44.00 and gave the company an “outperform” rating in a research report on Monday. TD Cowen assumed coverage on Kiniksa Pharmaceuticals International in a report on Monday, September 29th. They issued a “buy” rating and a $60.00 target price on the stock. Jefferies Financial Group upped their target price on Kiniksa Pharmaceuticals International from $45.00 to $54.00 and gave the company a “buy” rating in a report on Tuesday, July 29th. Zacks Research downgraded Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “hold” rating in a report on Monday, October 6th. Finally, Wall Street Zen lowered shares of Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a research note on Friday, October 3rd.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals International news, COO Eben Tessari sold 138,614 shares of the company’s stock in a transaction dated Tuesday, August 5th. The stock was sold at an average price of $33.20, for a total value of $4,601,984.80. Following the transaction, the chief operating officer directly owned 49,915 shares of the company’s stock, valued at $1,657,178. This represents a 73.52% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Michael R. Megna sold 17,000 shares of the company’s stock in a transaction dated Monday, August 4th. The stock was sold at an average price of $32.35, for a total value of $549,950.00. Following the completion of the transaction, the chief accounting officer directly owned 33,041 shares in the company, valued at approximately $1,068,876.35. The trade was a 33.97% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 584,471 shares of company stock valued at $19,892,061 in the last three months. Company insiders own 53.48% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. USA Financial Formulas acquired a new position in Kiniksa Pharmaceuticals International in the third quarter worth approximately $32,000. EverSource Wealth Advisors LLC increased its holdings in Kiniksa Pharmaceuticals International by 140.4% in the second quarter. EverSource Wealth Advisors LLC now owns 911 shares of the company’s stock worth $25,000 after buying an additional 532 shares during the last quarter. Osaic Holdings Inc. acquired a new position in Kiniksa Pharmaceuticals International in the second quarter worth approximately $31,000. GAMMA Investing LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 84.8% during the 1st quarter. GAMMA Investing LLC now owns 1,238 shares of the company’s stock worth $27,000 after purchasing an additional 568 shares during the last quarter. Finally, Farther Finance Advisors LLC increased its stake in shares of Kiniksa Pharmaceuticals International by 582.4% during the 3rd quarter. Farther Finance Advisors LLC now owns 1,358 shares of the company’s stock worth $53,000 after purchasing an additional 1,159 shares during the last quarter. 53.95% of the stock is owned by institutional investors and hedge funds.

Kiniksa Pharmaceuticals International Price Performance

KNSA stock opened at $37.89 on Friday. Kiniksa Pharmaceuticals International has a 52-week low of $17.82 and a 52-week high of $39.43. The company’s 50 day simple moving average is $35.48 and its 200-day simple moving average is $29.42. The firm has a market capitalization of $2.81 billion, a P/E ratio of 947.49 and a beta of 0.16.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last announced its earnings results on Tuesday, July 29th. The company reported $0.23 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.05. Kiniksa Pharmaceuticals International had a net margin of 0.90% and a return on equity of 1.05%. The company had revenue of $156.80 million for the quarter, compared to the consensus estimate of $145.21 million. Kiniksa Pharmaceuticals International has set its FY 2025 guidance at EPS. Sell-side analysts predict that Kiniksa Pharmaceuticals International will post -0.55 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.